Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
P/E Ratio
--
P/B Ratio
1.46
Industry P/E
--
Debt to Equity
--
ROE
-2.7 %
ROCE
-148.17 %
Div. Yield
0 %
Book Value
--
EPS
-1.29
CFO
$-509.24 Mln
EBITDA
$-637.82 Mln
Net Profit
$-619.94 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cara Therapeutic (CARA)
| -71.02 | -65.43 | -62.03 | -80.66 | -77.98 | -60.08 | -35.56 |
|
BSE Sensex*
| 2.55 | 3.66 | 4.54 | 7.47 | 12.04 | 19.65 | 11.42 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cara Therapeutic (CARA)
| -31.15 | -93.08 | -11.82 | -19.50 | -6.08 | 23.92 | 6.17 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,839.20 | -- | 38.11 | |
| 73.23 | 7,493.81 | 57.68 | 23.56 | |
| 60.43 | 11,518.55 | 396.8 | 0.76 | |
| 8.34 | 9,847.94 | -- | -3.24 |
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the... treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901 Read more
President, CEO & Director
Mr. Christopher A. Posner
President, CEO & Director
Mr. Christopher A. Posner
Headquarters
Stamford, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cara Therapeutic (CARA) stood at $ 44 Mln as on 31-Dec-24
The share price of Cara Therapeutic (CARA) is $5.32 (NASDAQ) as of 15-Apr-2025 16:00 EDT. Cara Therapeutic (CARA) has given a return of -77.98% in the last 3 years.
Cara Therapeutic (CARA) has a market capitalisation of $ 8 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cara Therapeutic (CARA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cara Therapeutic (CARA) and enter the required number of quantities and click on buy to purchase the shares of Cara Therapeutic (CARA).
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901
The CEO & director of Mr. Christopher A. Posner. is Cara Therapeutic (CARA), and CFO & Sr. VP is Mr. Christopher A. Posner.
There is no promoter pledging in Cara Therapeutic (CARA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Cara Therapeutic (CARA) | Ratios |
|---|---|
|
Return on equity(%)
|
-270.01
|
|
Operating margin(%)
|
-879.81
|
|
Net Margin(%)
|
-992.95
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cara Therapeutic (CARA) was $0 Mln.
$-11.33
(
